|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003392,
umls-concept:C0017262,
umls-concept:C0042172,
umls-concept:C0049065,
umls-concept:C0086418,
umls-concept:C0185117,
umls-concept:C0210492,
umls-concept:C0441655,
umls-concept:C0678222,
umls-concept:C1518174,
umls-concept:C1527027,
umls-concept:C1704675,
umls-concept:C1879547,
umls-concept:C2911684
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2003-3-13
|
|
pubmed:abstractText |
Genes that suppress tumorigenesis can be silenced by epigenetic events, such as aberrant DNA methylation and modification of chromatin structure. Inhibitors of DNA methylase and histone deacetylase (HDAC) can potentially reverse these events. The aim of this study was to determine the in vitro antineoplastic activity of 5-aza-2'-deoxycytidine (5-AZA-CdR), a potent inhibitor of DNA methylase, in combination with depsipeptide (depsi), an inhibitor of HDAC, on human breast carcinoma cells. We observed a synergistic antineoplastic interaction between 5-AZA-CdR and depsi in their capacity to inhibit colony formation of Hs578T and MCF-7 breast carcinoma cells. In order to understand the molecular mechanism of this interaction, we investigated the effect of these drugs on the activation of the 14-3-3sigma, E-cadherin and tissue inhibitor of metalloproteinase 3 (TIMP3) cancer-related genes, which were reported to be silenced by aberrant methylation in many breast tumor cell lines. 14-3-3sigma was reported to produce G cell cycle arrest following DNA damage. E-cadherin and TIMP3 function as suppressors of tumor metastasis. Semi-quantitative RT-PCR was used to determine the effect of the co-administration of 5-AZA-CdR and depsi on four breast carcinoma cell lines for the reactivation of these genes. We observed a synergistic activation of E-cadherin by the combination in Hs578T, MDA-MB-231 and MDA-MB-435 tumor cells. For 14-3-3sigma, we demonstrated an additive to synergistic activation by the combination for Hs578T and MDA-MB-435 tumor cells, respectively. In the MCF-7 tumor cells, the drug combination produced a synergistic activation of TIMP3. The association between the synergistic antineoplastic activity and the synergistic activation of the target genes in this study suggests that the mechanism of anticancer activity of 5-AZA-CdR, in combination with depsi, is probably related to their enhanced activation of different types of tumor suppressor genes that have been silenced by epigenetic events.(2)
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/14-3-3 Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Azacitidine,
http://linkedlifedata.com/resource/pubmed/chemical/Cadherins,
http://linkedlifedata.com/resource/pubmed/chemical/DNA,
http://linkedlifedata.com/resource/pubmed/chemical/DNA Modification Methylases,
http://linkedlifedata.com/resource/pubmed/chemical/Depsipeptides,
http://linkedlifedata.com/resource/pubmed/chemical/Exonucleases,
http://linkedlifedata.com/resource/pubmed/chemical/Histone Deacetylase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Peptides, Cyclic,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/SFN protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Tissue Inhibitor of...,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological,
http://linkedlifedata.com/resource/pubmed/chemical/decitabine,
http://linkedlifedata.com/resource/pubmed/chemical/romidepsin
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0959-4973
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2003 Lippincott Williams & Wilkins
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
193-202
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:12634613-14-3-3 Proteins,
pubmed-meshheading:12634613-Antineoplastic Agents,
pubmed-meshheading:12634613-Azacitidine,
pubmed-meshheading:12634613-Breast Neoplasms,
pubmed-meshheading:12634613-Cadherins,
pubmed-meshheading:12634613-Cell Line, Tumor,
pubmed-meshheading:12634613-DNA,
pubmed-meshheading:12634613-DNA Modification Methylases,
pubmed-meshheading:12634613-Depsipeptides,
pubmed-meshheading:12634613-Dose-Response Relationship, Drug,
pubmed-meshheading:12634613-Drug Synergism,
pubmed-meshheading:12634613-Exonucleases,
pubmed-meshheading:12634613-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:12634613-Histone Deacetylase Inhibitors,
pubmed-meshheading:12634613-Humans,
pubmed-meshheading:12634613-Inhibitory Concentration 50,
pubmed-meshheading:12634613-Neoplasm Proteins,
pubmed-meshheading:12634613-Peptides, Cyclic,
pubmed-meshheading:12634613-RNA, Messenger,
pubmed-meshheading:12634613-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:12634613-Tissue Inhibitor of Metalloproteinase-3,
pubmed-meshheading:12634613-Tumor Markers, Biological,
pubmed-meshheading:12634613-Tumor Stem Cell Assay
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Interaction of 5-aza-2'-deoxycytidine and depsipeptide on antineoplastic activity and activation of 14-3-3sigma, E-cadherin and tissue inhibitor of metalloproteinase 3 expression in human breast carcinoma cells.
|
|
pubmed:affiliation |
Département de Pharmacologie, Université de Montréal and Centre de Recherche Pédiatrique, Hôpital Sainte-Justine, Montréal, Québec, Canada.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
